A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market

Discovery of New Targeted Therapies Will Replace Conventional Therapies

USD 3,950

* Required Fields

USD 3,950

PAY BY INVOICE

Be the first to review this product

This study assesses marketed and in-research products and combination regimens for the lung cancer therapeutics market. Segmentation by drug class is provided, along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented by their mechanism of action against cancer. Cost-effective treatments and targeted therapies are the key unmet needs of the market.

Table of Contents

Executive SummaryExecutive SummaryExecutive Summary (continued)Executive Summary (continued)Methodology and ScopeMethodology and ScopeMarket OverviewMarket Overview—SegmentationMarket Overview—Segmentation (continued)Market Overview—Segmentation (continued)Recent Market DevelopmentsCompanies to WatchKey Merger, Acquisition, and Partnership AssessmentGame-changing StrategiesEpidemiologyEpidemiologyEpidemiology (continued)Epidemiology (continued)Competitive LandscapeCompetitive Landscape—Marketed and Pipeline Drugs in Pre-registration and Phase 3Competitive Landscape—Pipeline Drugs in Phase 1 and Phase 2Timeline of Product Launches/ApprovalTimeline of Patent ExpiriesCompetitive Landscape—Pivotal Clinical TrialsCompetitive Landscape—Pivotal Clinical Trials (continued)Marketed ProductsMarketed Products SynopsisMarketed Products Synopsis (continued)Marketed Products Synopsis (continued)Marketed Products Synopsis (continued)Pipeline Drugs AnalysisPipeline SynopsisPipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Product Dashboard of Recently Approved Drugs and Late-stage Pipeline Drug CandidatesProduct Dashboard: Tarceva® (Erlotinib)—Roche GroupProduct Dashboard: Gilotrif® (Afatinib)—Boehringer IngelheimProduct Dashboard: Avastin® (Bevacizumab)—Genentech Inc. (Roche Group)Product Dashboard: Alimta® (Pemetrexed)—Eli Lilly and CompanyProduct Dashboard: XALKORI® (Crizotinib)—Pfizer Inc.Product Dashboard: AP26113—Ariad Pharmaceuticals, Inc.Product Dashboard: Necitumumab—Eli Lilly and CompanyProduct Dashboard: Nivolumab—Bristol-Myers Squibb Company and Ono PharmaceuticalConclusionsConclusionsLegal DisclaimerAppendixAbout Lung CancerAbout Lung Cancer (continued)The Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition: Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.